Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 15, 2021updated 07 Jan 2022 7:09am

Lilly’s mirikizumab meets primary goal in Phase III ulcerative colitis trial

A greater decline from baseline in bowel urgency symptoms in subjects treated with mirikizumab were reported at one year.

Eli Lilly and Company has reported that its therapy, mirikizumab, met the primary and key secondary goals at one year in the Phase III LUCENT-2 clinical trial in moderately-to-severely active ulcerative colitis (UC) patients.

A humanised IgG4 monoclonal antibody, mirikizumab attaches to the p19 subunit of interleukin 23.

The randomised, multicentre, placebo-controlled, double-blind maintenance trial enrolled subjects who were part of the Phase III LUCENT-1 trial.

The latest data build on the positive results from the LUCENT-1 induction study for 12-weeks.

Findings from the LUCENT-2 trial showed that a statistically greater proportion of subjects treated with mirikizumab met the primary goal of clinical remission at one year versus those in the placebo arm.

Clinical remission is attained when colon inflammation is managed or resolved, resulting in normalisation or near-normalisation of symptoms, including frequent and bloody faeces.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The trial met all the key secondary goals. Significantly greater proportions of subjects in the mirikizumab arm attained endoscopic remission, resolution or near-resolution of bowel urgency, corticosteroid-free remission, endoscopic histologic intestinal inflammation improvement and remission maintenance.

Furthermore, a significant decline from baseline in bowel urgency symptoms at one year versus placebo were noted.

The overall safety profile of mirikizumab in the trial was in line with previously reported data from UC trials and others within the anti-IL-23p19 antibody class.

Nasopharyngitis, arthralgia and exacerbation of ulcerative colitis were the most commonly observed adverse events linked to mirikizumab.

Lilly immunology development and US and global medical affairs vice-president Lotus Mallbris said: “Existing therapies aren’t fully meeting the needs of people with ulcerative colitis who still have unresolved symptoms that impact their health and quality of life.

“These positive long-term results provide evidence that mirikizumab has the potential to be an effective treatment option and become the first medicine of its kind for people with ulcerative colitis, including those who suffer from bowel urgency.”

The company intends to submit these data as part of a Biologics License Application (BLA) to the US Food and Drug Administration for mirikizumab in UC indication.

It will also seek approvals from various other regulatory authorities across the globe in the first half of next year.

This July, Lilly reported that mirikizumab stimulated gene expression changes in individuals with UC over a 12-week induction treatment in the Phase II trial.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy